Try
Vaxcyte Inc. Common Stock
PCVXUnited States
25 filed reports · 332 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
25 reports · Jun 2020 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 19 | 2,842 | Jun 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 2,362 | Dec 2020 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 286 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 184 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 709 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 207 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 127 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 130 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 25, 2025 | 345 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 5, 2024 | 195 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 6, 2024 | 152 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 8, 2024 | 158 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 27, 2024 | 452 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 6, 2023 | 160 | Open |
Financial data
332 concepts · 5,204 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial323 concepts · 5,113 facts · Dec 2018 to Aug 2026
- Accrued manufacturing expenses44 · Dec 2019 to Dec 2025
- Stockholders equity (US GAAP)39 · Dec 2018 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value38 · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents38 · Dec 2018 to Jun 2026
- General and administrative expense (US GAAP)38 · Dec 2018 to Jun 2026
- Net income loss38 · Dec 2018 to Jun 2026
- Operating expenses (US GAAP)38 · Dec 2018 to Jun 2026
- Operating income loss38 · Dec 2018 to Jun 2026
- Other nonoperating income expense38 · Dec 2018 to Jun 2026
- Research and development expense38 · Dec 2018 to Jun 2026
- Investment income interest37 · Dec 2018 to Jun 2026
- Net income loss available to common stockholders basic37 · Dec 2018 to Jun 2026
- Accrued compensation36 · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect36 · Dec 2018 to Jun 2026
- Depreciation depletion and amortization36 · Dec 2018 to Jun 2026
- Increase decrease in accounts payable36 · Dec 2018 to Jun 2026
- Increase decrease in accrued liabilities36 · Dec 2018 to Jun 2026
- Increase decrease in other operating assets36 · Dec 2018 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets36 · Dec 2018 to Jun 2026
- Net cash provided by used in financing activities36 · Dec 2018 to Jun 2026
- Net cash provided by used in investing activities36 · Dec 2018 to Jun 2026
- Net cash provided by used in operating activities36 · Dec 2018 to Jun 2026
- Payments to acquire property plant and equipment36 · Dec 2018 to Jun 2026
- Profit loss36 · Dec 2018 to Jun 2026
Segment7 concepts · 64 facts · Dec 2022 to Jun 2026
- General and administrative expense (US GAAP)14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Operating expenses (US GAAP)14 · Dec 2022 to Jun 2026
- Nonoperating income expense13 · Dec 2023 to Jun 2026
- Acquired manufacturing rights (Note 7)4 · Dec 2022 to Dec 2025
- Other nonoperating income expense3 · Dec 2022 to Dec 2024
- Reportable Segment2 · Jun 2025 to Jun 2026
Geography1 concepts · 19 facts · Dec 2023 to Jun 2026
- Property, Plant & Equipment, Net19 · Dec 2023 to Jun 2026
Product1 concepts · 8 facts · Sep 2020 to Dec 2021
- Pneumococcal Conjugate Vaccine8 · Sep 2020 to Dec 2021
Segments
91 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 64 facts
- Reportable64 · Dec 2022 to Jun 2026
Statement geographical2 members · 19 facts
- Us10 · Dec 2023 to Jun 2026
- Ch9 · Dec 2024 to Jun 2026
Product or service1 member · 8 facts
- Pneumococcal Conjugate Vaccine8 · Sep 2020 to Dec 2021
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary120 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary153 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes17 claims from 1 reports · Dec 2025
- Risk factors143 risks from 2 annual reports · 2024 to 2025
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.